1. Medicine

Category Archives: Medicine

Best In-Vitro Fertilization Treatment Clinic | Reproductive Medicine Center Kerala – Video

Posted on by


Best In-Vitro Fertilization Treatment Clinic | Reproductive Medicine Center Kerala
http://www.ivf-clinic-india.com Asian Reproductive Medicine Center provides In-Vitro Fertilization treatment. IVF procedure is more applicable for females fa...

By: Kunjumoideen K.U.

Go here to see the original:

Best In-Vitro Fertilization Treatment Clinic | Reproductive Medicine Center Kerala - Video

Maine Center for Cancer Medicine: On the Leading Edge of Cancer Treatment with IBM Watson

Posted on by

S. PORTLAND, Maine--(BUSINESS WIRE)--

More than 1.6 million new cancer cases will be diagnosed in the U.S. this year alone, according the American Cancer Society. It is estimated that new clinical research and medical information doubles every five years, and nowhere is this knowledge advancing more quickly than in the complex area of cancer care.

The Maine Center for Cancer Medicine (MCCM) is exploring the capabilities of Interactive Care Insights for Oncology, a new product developed by Anthems parent company, IBM and Memorial Sloan Kettering that utilizes IBMs Watson technology and Memorial Sloan-Ketterings clinical expertise.The Watson capability, available through the cloud or on premise, is expected to assist medical professionals and researchers by helping to identify individualized treatment options for patients with cancer, starting with lung cancer. The solution provides users with a detailed record of the data and information used to reach the treatment options. MCCM will tap into IBM Watson's ability to understand the nuances of human language, process questions akin to the way people think, and quickly cull through vast amounts of Big Data for relevant, evidence-based answers.

Interactive Care Insights for Oncology will bring real-time decision support to oncologists by using natural language processing capabilities to pull in all the medical information available about a specific patient, synthesize it, and then compare it with clinical evidence and cancer treatment guidelines, providing a more patient-specific and actionable clinical interpretation. Ultimately, the Watson-powered solutioncould help physicians to select the most effective treatment option while streamlining health plan approvals.

We are honored to have been asked to partner with IBM and Anthems parent company in bringing the IBM Watson technology to health care in Maine, said Tracey Weisberg, M.D., MCCM. The Watson technology, along with Memorial Sloan-Ketterings clinical expertise will bring more relevant oncologic information to the physician and patient, making treatment planning more comprehensive.

"IBM's work with MCCM and Anthem's parentis a great example of how technology and evidence based medicine can transform the way in which health care is practiced," said Manoj Saxena, IBM General Manager, Watson Solutions. "These breakthrough capabilities bring forward the first in a series of Watson-based technologies, which exemplifies the value of applying big data and analytics and cognitive computing to tackle the industrys most pressing challenges."

MCCM is providing Anthems parent company and Memorial Sloan-Kettering with valuable feedback that will shape thenext version of theproduct. Oncologists at MCCM will focus their attention onWatson's unique capabilities, such as how Watson presents information to the physician, and if the data is displayed in an actionableway and in logical order. Using these insights, the MCCM oncologistswill recommend features that will ultimately improve the usability of the product.

Our goal is to provide oncologists tools to help select the most effective treatment options for their patients and were excited to work with MCCM in this endeavor, said Dan Corcoran, president and general manager, Anthem Blue Cross and Blue Shield in Maine. Their perspective is essential in ensuring the product utilizing IBMs Watson technology and Memorial Sloan-Ketterings clinical expertise will benefit physicians and ultimately, their patients.

According to the American Cancer Society, nearly 9,000 new cancer cases were diagnosed in Maine 2012.

We are also dedicated to innovation and directly apply such treatments, technologies and support models to the patient care experience whenever appropriate, noted Dr. Weisberg. Our collaboration with Anthem to test this new product developed by Anthems parent company, Memorial Sloan Kettering and IBM builds on our belief that innovation can truly transform health care.

Continued here:

Maine Center for Cancer Medicine: On the Leading Edge of Cancer Treatment with IBM Watson

Five Hundred Thirty-Seven New Diplomates Certified by American Board of Addiction Medicine

Posted on by

Chicago, Illinois (PRWEB) June 12, 2013

The American Board of Addiction Medicine (ABAM) was proud to honor and recognize 537 physicians who achieved board certification in addiction medicine during the organizations recent annual awards luncheon in Chicago, IL. The new ABAM diplomates join 2,557 physicians in the United States who have already been certified and awarded diplomate status by ABAM, an independent medical specialty board.

ABAM certifies addiction medicine physicians from all medical specialties, including emergency medicine, family medicine, internal medicine, obstetrics and gynecology, pediatrics, preventive medicine, psychiatry, neurology and surgery. Prior to the establishment of ABAM, psychiatrists were the only specialists who had addiction-related board certification available to them. ABAM also sets standards for physician education, assesses physicians knowledge, and requires and tracks Maintenance of Certification through life-long continuous education.

We want addiction prevention, screening, intervention and treatment to become routine aspects of medical care, available virtually any place health care is provided, said Jeffrey Samet, MD, President of the American Board of Addiction Medicine.

One in five Americans entering the health care system has a substance abuse problem. The American Board of Addiction Medicine is the only medical specialty board that both draws from all areas of medicine and is dedicated to certifying addiction specialists. By seeking ABAM-certified addiction physician specialists, patients have a way to find specialized medical care for substance use disorders related to alcohol, tobacco and other addicting drugs, including some prescription medications.

Physicians are often at a loss for what to do about substance use and addiction issues, and may even misdiagnose the problem, said Dr. Samet. We hope to change this by creating a cadre of thousands of specialized physicians across medical specialties.

Studies show that fewer than one in five physicians consider themselves adequately prepared to diagnose alcoholism or other drug use disorders. Physician training is sorely lacking. Separate courses in addiction medicine are rarely taught in medical school, and there are no addiction medicine residencies among the 8,200 American Council for Graduate Medical Education (ACGME) accredited residency programs in the nations hospitals.

The American Board of Addiction Medicine provides assurance to the American public that addiction medicine physicians have the knowledge and skills to prevent, recognize and treat addiction, said Dr. Samet. ABAM-certified physicians will also be able to address common medical or psychiatric conditions related to the use of addictive substances.

Created in 2007, with the encouragement of the American Society of Addiction Medicine, ABAM offers a rigorous certifying examination that was developed by an expert panel and the National Board of Medical Examiners, as well as annual Maintenance of Certification requirements to ensure that ABAM-certified physicians maintain life-long competence in addiction medicine.

ABAM has a governing body of 15 distinguished physicians from across a range of medical specialties, each of whom is certified by a member board of the American Board of Medical Specialties (ABMS). ABAM is in the process of seeking recognition from ABMS, and plans to certify physicians in multiple specialties. ABAM has taken steps to assist in the creation of addiction medicine training programs affiliated with the nations top medical schools. Eighteen of these programs are now accredited by The ABAM Foundation.

The rest is here:

Five Hundred Thirty-Seven New Diplomates Certified by American Board of Addiction Medicine

Albert Einstein College of Medicine hosts conference on Jewish genetic research

Posted on by

Public release date: 11-Jun-2013 [ | E-mail | Share ]

Contact: Deirdre Branley sciencenews@einstein.yu.edu 718-430-3101 Albert Einstein College of Medicine

June 11, 2013 (BRONX, NY) Today, researchers at Albert Einstein College of Medicine of Yeshiva University convened a one-day conference on Jewish genetics designed to encourage collaboration and advance the field of research. Such research could help scientists identify causes and potential treatments for population-specific diseases as well as more common disorders afflicting the general population.

The genetic makeup of Ashkenazi Jews is relatively homogenous, which makes it easier to identify gene variations that cause disease. By bringing together scientists who investigate Jewish genetics with those at disease-specific research centers, the conference organizers hope to encourage new, productive research partnerships that could uncover the causes of debilitating conditions.

Twenty researchers from ten institutions are participating. From diabetes and arthritis to intellectual disabilities and Alzheimer's disease, a range of disorders are represented. Scientists studying Jewish genetics as well as those working with Latino/Hispanic, Amish and other racial and ethnic groups will also attend.

"We would like to see new research centers or other large-scale, multi-investigator studies established that can mine Jewish genomic data for clues to disease," said Harry Ostrer, M.D., one of the conference organizers and professor of pathology, of genetics, and of pediatrics at Einstein and director of genetic and genomic testing at Montefiore Medical Center, the University Hospital for Einstein.

"Several fruitful collaborations have already occurred in the field including the Jewish HapMap Project and The Ashkenazi Genome Consortium and we would like to expand that," noted Gil Atzmon, Ph.D., associate professor of medicine at Einstein.

In addition to Drs. Ostrer and Atzmon, other organizers of the conference are Nicole Schreiber-Argus, Ph.D., assistant professor of genetics at Einstein and Itsik Pe'er, Ph.D., at Columbia University.

The one-day event is titled "Genetic Research and Discovery in Jewish Populations: Toward Large-Scale Sustainable Efforts."

###

Read the original here:

Albert Einstein College of Medicine hosts conference on Jewish genetic research

Companion Diagnostics and Other Aspects of Personalized Medicine

Posted on by

NEW YORK, June 11, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Companion Diagnostics and Other Aspects of Personalized Medicine http://www.reportlinker.com/p01277476/Companion-Diagnostics-and-Other-Aspects-of-Personalized-Medicine.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

The focus of this report is the use of personalized medicine for pharmacological/diagnostic combinations; particularly pharmacological therapies and the diagnostic tests, which can provide information on the likelihood of a patient to respond to specific treatments.

Historically, drugs have been developed on a "one-size-fits-all" basis, but due to patients responding differently to the same drug and having potentially life threatening side effects, new therapies have been developed for approaching the treatment of diseases. Such an approach is with personalized medicine. Personalized medicine is an all-encompassing term for focused treatments in diseases. While in some areas, personalized medicine may focus on an inpidual's genome in response to therapy, in others it may be broader and focus on tailoring a medical treatment to the characteristics of each patient. Often in the form of drug/diagnostic combinations, personalized medicine is commonly used in treating breast cancer. Such an example is using estrogen and progesterone receptors, which are biomarkers, in combination with immunochemistry tests to determine an appropriate therapy. Other methods of personalized medicine for breast cancer include testing for HER2/neu overexpression as well as testing for the presence of multiple genes. With drug/diagnostic combinations, physicians can identify patients who are likely to respond to specific treatments.

With personalized medicine becoming a more effective form of treatment, more diagnostic tests are being developed to use in combination with pharmacology. Using this form of treatment, physicians not only target the proper disease with the proper therapy, but patients are also less likely to develop adverse reactions and life threatening side effects.

Main concepts of personalized medicine covered in this report include: Various definitions of personalized medicine Range of disease applications for personalized medicine Use of personalized medicine in research and development Technologies used in personalized medicine testing Examples of drug/diagnostic combinations currently in use Examples of drug/diagnostic combinations in development Development of diagnostic and therapeutic products Extensive tables which include information on diagnostic companies that market personalized medicine in vitro diagnostic tests and/or services through their own CLIA laboratory Survey of 157 participants (including pharmaceutical/biopharmaceutical companies, diagnostic companies, CROs, universities or research institutes, clinical/reference/hospital laboratories, among others) with experience working with personalized medicine Interviews with pharmaceutical and diagnostic companies actively participating in personalized medicine

About the Author Lucy J. Sannes, PhD, MBA, is president of Sannes & Associates, a consulting firm specializing in evaluation and management of the biosciences. Before forming Sannes & Associates, she held management positions at Genetic Systems and Abbott Laboratories in product development, product support, and technical marketing. Dr. Sannes received her PhD in biological chemistry from the University of Michigan and her MBA from Seattle Pacific University.

Table of Contents

Introduction Executive Summary

Chapter 1 Introduction

Follow this link:

Companion Diagnostics and Other Aspects of Personalized Medicine

BG Medicine Welcomes Inclusion of Galectin-3 as Biomarker of Myocardial Fibrosis in 2013 ACCF/AHA Guideline for …

Posted on by

WALTHAM, Mass., June 12, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (BGMD) announced today that galectin-3 testing has been recognized for the first time in the newly issued 2013 American College of Cardiology Foundation and the American Heart Association (ACCF/AHA) Guideline for the Management of Heart Failure. The ACCF/AHA Guideline is designed to assist clinicians in selecting the best management strategy for individual patients and provides expert analysis of data on prevention, diagnosis, risk stratification, and treatment.

Galectin-3 testing has been assigned a Level of Evidence of 'A', multiple populations evaluated, and a Class of Recommendation corresponding to 'May Be Considered' for the purpose of additive risk stratification of acute heart failure patients, and a Level of Evidence of 'B', limited populations evaluated, and a Class of Recommendation of 'May Be Considered' for risk stratification of ambulatory heart failure patients.

The guideline further notes that testing for galectin-3 is predictive of risk of adverse outcomes in heart failure, including hospitalization, and is additive to BNP and NT-proBNP testing for heart failure patient risk stratification.

"We believe that the inclusion of galectin-3 in the updated ACCF/AHA Guideline is an important recognition of the potential significance of galectin-3 in the evaluation and management of patients with heart failure," commented Paul Sohmer, M.D., President and Chief Executive Officer of BG Medicine.

About American College of Cardiology Foundation and the American Heart Association (ACCF/AHA) Guideline for the Management of Heart Failure

The American College of Cardiology Foundation (ACCF) and the American Heart Association (AHA) have jointly produced guidelines in the area of cardiovascular disease since 1980. The ACCF/AHA Task Force on Practice Guidelines is charged with developing, updating and revising practice guidelines for cardiovascular diseases and procedures. Writing committees are charged with regularly reviewing and evaluating all available evidence to develop balanced, patient-centric recommendations for clinical practice. The guidelines for heart failure management were last published in 2009.

The 2013 ACCF/AHA Guideline for the Management of Heart Failure is currently available online at http://circ.ahajournals.org/content/early/2013/06/03/CIR.0b013e31829e8807 and will be published in the August 27, 2013 print issue of the Journal of the American College of Cardiology (JACC).

About Galectin-3 Testing

Galectin-3 has been implicated in a variety of biological processes important in the development and progression of heart failure. Higher levels of galectin-3 are associated with a more aggressive form of heart failure, which may make identification of high-risk patients using galectin-3 testing an important part of patient care. Galectin-3 testing may be useful in helping physicians determine which patients are at higher risk of death or hospitalization, including 30-day readmission. http://www.galectin-3.com

About BG Medicine, Inc.

Read the original here:

BG Medicine Welcomes Inclusion of Galectin-3 as Biomarker of Myocardial Fibrosis in 2013 ACCF/AHA Guideline for ...

Scholarship in Personalized Medicine Awarded at the University of British Columbia

Posted on by

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jun 11, 2013) - During the opening of the Personalized Medicine and Individualized Drug Delivery conference at the University of British Columbia today, the $50,000 Ronnie Miller Scholarship in Personalized Medicine was presented to a deserving student studying life sciences at the University. Mr. Ronnie Miller, past Chair of the Rx&D Board (2011) and President and CEO, Hoffmann-La Roche Limited, Dr. Roger Brownsey, Department Head, Biochemistry & Molecular Biology, Dr. Pieter Cullis, Professor, Biochemistry and Molecular Biology, and Mr. John Willow, Regional Director for British Columbia, Canada's Research-Based Pharmaceutical Companies (Rx&D) were on hand for the presentation.

"My colleagues and I in the Department of Biochemistry and Molecular Biology and the Faculty of Medicine at UBC are extremely grateful to Rx&D and Hoffmann-La Roche for their wonderful act of generosity and foresight in making this donation. The support of young trainees is critical and yet remains a continuing challenge. Providing such support for one of our brightest young scientists will pay huge dividends in the future and is one of the best investments we can make," said Dr. Brownsey.

The Scholarship was awarded to Joslyn Quick, who is focusing her work on the treatment of advanced prostate cancer in the hopes that treatments eventually be tailored to a patient's own genetic profile.

The Ronnie Miller Scholarship in Personalized Medicine has been created in honour of Mr. Ronnie Miller, past Chair of the Rx&D Board (2011) and President & CEO, Hoffmann-La Roche Limited. It was awarded to a graduate student of the Department of Biochemistry and Molecular Biology at the University of British Columbia, whose work will provide a significant contribution to the British Columbia Personalized Medicine Initiative (BCPMI). Rx&D and Hoffmann-La Roche Limited have each contributed $25,000, for a total of $50,000 over 5 years.

"I am very proud of this scholarship program, and am excited by what the next generation of scientists will do to further advance personalized healthcare," added Mr. Miller. "At Roche, personalized healthcare is about improving understanding of the disease and the patient to deliver precision medicine. It is about the right treatment at the right time for the right patient. To us, it means using the combined strength of our pharmaceutical and diagnostics arms to deliver better diagnosis, better treatments and, most importantly, better results."

About Rx&D

Rx&D is the association of leading research-based pharmaceutical companies dedicated to improving the health of Canadians through the discovery and development of new medicines and vaccines. Our community represents the men and women working for more than 50 member companies which invest more than $1 billion in research and development each year to fuel Canada's knowledge-based economy, contributing over $3 billion to the Canadian economy. Guided by our Code of Ethical Practices, our membership is committed to working in partnership with governments, healthcare professionals and stakeholders in a highly ethical manner.

See original here:

Scholarship in Personalized Medicine Awarded at the University of British Columbia

Moores Cancer Center: Transforming Cancer Therapy With Personalized Medicine – Video

Posted on by


Moores Cancer Center: Transforming Cancer Therapy With Personalized Medicine
Our goal is to transform cancer therapy by matching patients with the best drug for their particular tumor. Personalized therapy is here, but we need help fr...

By: UCSDMedicalCenter

See the rest here:

Moores Cancer Center: Transforming Cancer Therapy With Personalized Medicine - Video


  1. Medicine